Navigation Links
Preterm birth: Magnesium sulphate cuts cerebral palsy risk
Date:1/20/2009

Magnesium sulphate protects very premature babies from cerebral palsy, a new study shows. The findings of this Cochrane Review could help reduce incidence of the disabling condition, which currently affects around one in every 500 newborn babies overall, but up to one-in-ten very premature babies (< 28 weeks of gestation).

The neuroprotective function of magnesium in preterm babies was first suggested in the early nineties. Cochrane Researchers who carried out a systematic review of the available evidence say this role is now established. Magnesium sulphate is usually given as a slow infusion through a vein, but can also be given as an injection into the muscle.

"There is now enough evidence to support giving magnesium sulphate to women at risk of very preterm birth as a protective agent against cerebral palsy for their baby," said lead researcher, Lex Doyle, who works at the Department of Obstetrics and Gynaecology at the Royal Women's Hospital and the University of Melbourne in Australia.

Exactly how magnesium protects the brain is not certain, but it is essential for many processes that keep cells working normally, it may protect against harmful molecules that can damage or kill cells, and it improves blood flow under some circumstances.

The researchers reviewed data from five trials of antenatal magnesium sulphate therapy, which together included 6,145 babies. Overall 63 women at risk of very preterm birth had to be given magnesium sulphate to prevent one case of cerebral palsy in the baby.

Side effects of the treatment include flushing, sweating, nausea, vomiting, headaches and palpitations. However, the researchers found no increase in major complications in mothers due to magnesium therapy.


'/>"/>

Contact: Jennifer Beal
wbnewseurope@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Page: 1

Related biology news :

1. Uncultured bacteria found in amniotic fluids of women who experience preterm births
2. Depression during pregnancy can double risk of preterm delivery
3. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
4. Analysis of millions of US births shows association between birth defects and preterm birth
5. Risk of common vaginal infection linked to preterm birth appears higher for blacks
6. MSU researcher helps develop computer game for Ugandan children recovering from cerebral malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):
(Date:2/25/2017)... ... February 25, 2017 , ... ... Trials in an ongoing effort to create meaningful change by increasing communication, ... research with emphasis on consumers and patients’ mental health well-being. , Both organizations ...
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company ... National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month ... technology and is expected to deliver therapeutic levels of olanzapine for a period of ...
(Date:2/24/2017)... 24, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... participate in its previously announced rights offering of ... of common stock and Series C Convertible Preferred ... warrants. As previously announced, the ...
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
Breaking Biology Technology: